G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
NCT06556940 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2025-01-09
Summary
The goal of this interventional study is to learn about the intraluminal pharmacokinetics (PK) of the investigational drug LMN-401 in adult healthy volunteers with ileostomies. LMN-401 is being developed as a potential new treatment for Traveler's Diarrhea. The study will also learn about the safety of the investigational drug LMN-401.
The main questions it aims to answer are:
* What is the timing and amount of components of investigational drug LMN-401 detected in the collected ileostomy material?
* Is LMN-401 safe and well tolerated in healthy volunteers taking the investigational drug?
Researchers will compare the timing and amount of investigational drug components detected in the ileostomy material in volunteers taking the investigational drug LMN-401 formulated into tablets with different properties. The impact of the study participant's fed or fasted state on the timing and amount of drug components detected in the ileostomy material will also be evaluated.
Each study participant will come into the research clinic for four study visits. Study participants will receive the investigational product formulated into tablets with different properties. Ileostomy material will be collected at baseline (pre-dose) and every two hours after investigational product dose administration for 10 hours.
Conditions
- Travelers Diarrhea
Interventions
- BIOLOGICAL
-
LMN-401
Orally delivered tablets and capsules
Sponsors & Collaborators
-
Lumen Bioscience, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-12-04
- Primary Completion
- 2025-10-02
- Completion
- 2025-12-02
Countries
- Australia
Study Locations
More Related Trials
-
Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.
NCT04910061 ·Status: COMPLETED ·Phase: NA
-
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
NCT02421042 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health Volunteers
NCT06570668 ·Status: COMPLETED ·Phase: PHASE1
-
Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers
NCT01176851 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects
NCT01124279 ·Status: COMPLETED ·Phase: PHASE1
-
Gut Transit Effect on Enterohepatic Circulation
NCT03501498 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
NCT03440424 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects
NCT02392702 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
NCT02372084 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT03902002 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects
NCT05119790 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02412098 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants
NCT05607537 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers
NCT07110441 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
NCT06520553 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
NCT01967966 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
NCT04674826 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NST-6179 in Healthy Subjects
NCT05181085 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers
NCT04156646 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101
NCT01462786 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217)
NCT05181241 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults
NCT03264079 ·Status: COMPLETED ·Phase: PHASE1